Owners, management and financials
CVR: 32287824
Secondary names: NORDMEDICA INTERNATIONAL A/S, Atnahs Pharma Nordics A/S, Pharmanovia Nordics A/S
Previous names: NMAS A/S, NORDMEDICA INTERNATIONAL A/S, PHARMANOVIA A/S
EUR 11,734,813
Gross profit
Net result: EUR 7,730,657
Atnahs Pharma UK Limited (100%)
CVR · view owners
Christoph Michael Habereder
Board: Mohammad Muqtadir Samy (chair) and 2 members
CVR · view management
Active
Founded 6 July 2009
CVR · view overview
3 employees
CVR · 2026
Director role ended: Neeshe Bhikhubhai Williams
CVR · 09/06/2026
View the full event history
Pharmanovia A/S is a Danish company of the type Aktieselskab based in København S, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Atnahs Pharma Nordics A/S and PHARMANOVIA A/S. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. The company has 3 employees (2026). In 2026, the company reported a gross profit of EUR 11,734,813 and a net result of EUR 7,730,657 compared with DKK 3,839,334 the year before. Equity in the 2026 report amounted to EUR 15,820,601.
Source: annual report 2026, Danish Business Authority
Pharmanovia A/S has shown a significant recovery in financial health, transitioning from a negative equity position in 2022 to a robust equity of 15,820,601 EUR in 2026. The company has demonstrated impressive growth in gross profit, increasing from 3,431,174 DKK in 2022 to 43,983,779 DKK in 2023, and further to 11,734,813 EUR in 2026, indicating a strong upward trend in profitability. Despite the absence of disclosed revenue figures, the consistent profit growth—from a loss of 21,600,385 DKK in 2022 to a profit of 7,730,657 EUR in 2026—highlights effective cost management and operational efficiency. The company's improving margins and solid equity position suggest a strengthening foothold in the pharmaceutical wholesale industry, although the lack of revenue transparency remains a concern.
AI-generated summary · Generated 01/10/2026
Selskabets formål er at drive handelsvirksomhed med farmaceutiske produkter, herunder udvikling, salg, distribution og markedsføring af farmaceutiske produkter og dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202601/04/2025 – 31/03/2026 | 11.7 mio. EUR | 7.7 mio. EUR | 32.3 mio. EUR | 15.8 mio. EUR | 9 | |
| 202501/04/2024 – 31/03/2025 | 6 mio. | 3.8 mio. | 39.9 mio. | 8.1 mio. | 12 | |
| 202401/04/2023 – 31/03/2024 | 4.7 mio. EUR | 2.2 mio. EUR | 47.7 mio. EUR | 4.9 mio. EUR | 12 | |
| 202301/04/2022 – 31/03/2023 | 44 mio. | 26.1 mio. | 136.7 mio. | 19.6 mio. | 15 | |
| 202201/04/2021 – 31/03/2022 | 3.4 mio. | -21.6 mio. | 76.1 mio. | -6.5 mio. | 18 | |
| 202101/04/2020 – 31/03/2021 | 15.2 mio. | -2 mio. | 27.9 mio. | 15.1 mio. | 15 | |
| 202001/04/2019 – 31/03/2020 | 3.7 mio. | -13.7 mio. | 29.2 mio. | 17.1 mio. | 12 | |
| 201901/04/2018 – 31/03/2019 | 10.6 mio. | -5.9 mio. | 24.7 mio. | -19.9 mio. | 12 | |
| 201801/04/2017 – 31/03/2018 | 2.6 mio. | -9.2 mio. | 23.9 mio. | -14 mio. | 8 | |
| 201501/01/2015 – 31/12/2015 | 1.5 mio. | -2.2 mio. | 18.7 mio. | -12.3 mio. | 4 | |
| 201401/01/2014 – 31/12/2014 | -609 t. | -3.4 mio. | 13.1 mio. | -10.2 mio. | 4 | |
| 201301/01/2013 – 31/12/2013 | -1.2 mio. | -6.7 mio. | 14.8 mio. | -6.8 mio. | - | |
| 201201/01/2012 – 31/12/2012 | -157 t. | -586 t. | 11.7 mio. | -60 t. | - |
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
3 public tenders won
Sources: TED (the EU tender database) and udbud.dk
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Pharmanovia A/S is 32287824.
Pharmanovia A/S is owned by Atnahs Pharma UK Limited.
The management of Pharmanovia A/S consists of Christoph Michael Habereder.
The board of Pharmanovia A/S consists of Mohammad Muqtadir Samy, Christoph Michael Habereder and Twan Johannes Anna Nouwen, with Mohammad Muqtadir Samy as chair.
In 2026, Pharmanovia A/S reported a gross profit of EUR 11,734,813.
Pharmanovia A/S had 3 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Pharmanovia A/S has published its annual report for 2026. Gross profit came to DKK 11,734,813, and the net result was DKK 7,730,657.
As of June 9, 2026, Neeshe Bhikhubhai Williams has left the board of directors of Pharmanovia A/S.
As of June 9, 2026, Christoph Michael Habereder is registered as director of Pharmanovia A/S.
As of June 9, 2026, Neeshe Bhikhubhai Williams has stepped down as director of Pharmanovia A/S.
As of March 24, 2026, Mohammad Muqtadir Samy has joined the board of directors of Pharmanovia A/S.
As of March 24, 2026, Amit Vijaykumar Patel has left the board of directors of Pharmanovia A/S.
As of March 23, 2026, Mohammad Muqtadir Samy has left the board of directors of Pharmanovia A/S.
As of February 17, 2026, Twan Johannes Anna Nouwen has joined the board of directors of Pharmanovia A/S.
As of February 17, 2026, Mohammad Muqtadir Samy has joined the board of directors of Pharmanovia A/S.
As of February 17, 2026, Christoph Michael Habereder has joined the board of directors of Pharmanovia A/S.
As of February 17, 2026, Santsagar Patel has left the board of directors of Pharmanovia A/S.
As of November 26, 2025, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Pharmanovia A/S.
As of November 26, 2025, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2025. Gross profit came to DKK 6,024,928, and the net result was DKK 3,839,334.
Pharmanovia A/S has won the tender "Amgros 2026 1.1202.a" issued by Amgros I/S worth 383,606,720 DKK.
Pharmanovia A/S has won the tender "Amgros 2026 1.1203.a" issued by Amgros I/S worth 368,505,024 DKK.
As of September 30, 2025, James Sang Bum Lee has left the board of directors of Pharmanovia A/S.
As of September 30, 2025, Zubair Javeed has left the board of directors of Pharmanovia A/S.
As of September 30, 2025, Neeshe Bhikhubhai Williams is registered as director of Pharmanovia A/S.
As of September 30, 2025, James Sang Bum Lee has stepped down as director of Pharmanovia A/S.
As of August 25, 2025, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Pharmanovia A/S.
As of August 19, 2025, KPMG P/S has stepped down as auditor of Pharmanovia A/S.
As of May 1, 2025, Zubair Javeed has joined the board of directors of Pharmanovia A/S.
As of May 1, 2025, Santsagar Patel has joined the board of directors of Pharmanovia A/S.
As of May 1, 2025, James Charles Burt has left the board of directors of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2024. Gross profit came to DKK 4,683,828, and the net result was DKK 2,246,626.
Pharmanovia A/S has won the tender "Amgros 2024 1.1219.a" issued by Amgros I/S worth 2,340,000 DKK.
Pharmanovia A/S has published its annual report for 2023. Gross profit came to DKK 43,983,779, and the net result was DKK 26,130,781.
As of October 6, 2023, James Sang Bum Lee is registered as director of Pharmanovia A/S.
As of October 6, 2023, Jesper Wilhelm Voss has stepped down as director of Pharmanovia A/S.
As of May 24, 2023, James Sang Bum Lee has joined the board of directors of Pharmanovia A/S.
As of May 24, 2023, Felipe Andres Florez Arango has left the board of directors of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2022. Gross profit came to DKK 3,431,174, and the net result was DKK -21,600,385.
As of March 29, 2022, Rishi Bhikhu has left the board of directors of Pharmanovia A/S.
As of December 17, 2021, James Charles Burt has joined the board of directors of Pharmanovia A/S.
As of December 17, 2021, Alastair Thomas Badgett Hay has left the board of directors of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2021. Gross profit came to DKK 15,223,656, and the net result was DKK -2,028,136.
As of June 16, 2021, Felipe Andres Florez Arango has joined the board of directors of Pharmanovia A/S.
On June 16, 2021, the company changed its name from Atnahs Pharma Nordics A/S to Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2020. Gross profit came to DKK 3,730,176, and the net result was DKK -13,715,317.
On June 18, 2020, the company changed its name from PHARMANOVIA A/S to Atnahs Pharma Nordics A/S.
As of February 24, 2020, Anthony Charles Playle has left the board of directors of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2019. Gross profit came to DKK 10,613,509, and the net result was DKK -5,891,089.
As of August 7, 2019, Neeshe Bhikhubhai Williams has joined the board of directors of Pharmanovia A/S.
As of August 7, 2019, Rishi Bhikhu has joined the board of directors of Pharmanovia A/S.
As of August 7, 2019, Alastair Thomas Badgett Hay has joined the board of directors of Pharmanovia A/S.
As of August 7, 2019, Dipen Vijaykumar Patel has left the board of directors of Pharmanovia A/S.
As of August 7, 2019, Mark John Cotterill has left the board of directors of Pharmanovia A/S.
As of February 28, 2019, Mark John Cotterill has joined the board of directors of Pharmanovia A/S.
As of February 28, 2019, Svend Aage Johansen has left the board of directors of Pharmanovia A/S.
As of February 28, 2019, Jesper Wilhelm Voss is registered as director of Pharmanovia A/S.
As of February 28, 2019, Svend Aage Johansen has stepped down as adm. dir. of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2018. Gross profit came to DKK 2,645,762, and the net result was DKK -9,237,568.
As of February 28, 2018, is registered as an owner of Pharmanovia A/S with an ownership share of 100%.
Pharmanovia A/S has published its interim report for the period January 1, 2016 to March 31, 2017.
Pharmanovia A/S has published its annual report for 2015. Gross profit came to DKK 1,474,795, and the net result was DKK -2,189,034.
As of April 20, 2016, KPMG P/S has been appointed auditor of Pharmanovia A/S.
As of April 20, 2016, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Pharmanovia A/S.
As of March 31, 2016, Amit Vijaykumar Patel has joined the board of directors of Pharmanovia A/S.
As of March 31, 2016, Dipen Vijaykumar Patel has joined the board of directors of Pharmanovia A/S.
As of March 31, 2016, Anthony Charles Playle has joined the board of directors of Pharmanovia A/S.
As of March 31, 2016, Bent Benny Andersen has left the board of directors of Pharmanovia A/S.
As of March 31, 2016, Birgitte Stenbjerre has left the board of directors of Pharmanovia A/S.
As of March 31, 2016, Mads Christian Olesen has left the board of directors of Pharmanovia A/S.
As of January 1, 2016, Svend Aage Johansen has joined the board of directors of Pharmanovia A/S.
As of January 1, 2016, Bent Benny Andersen has joined the board of directors of Pharmanovia A/S.
As of January 1, 2016, Svend Aage Johansen is registered as adm. dir. of Pharmanovia A/S.
As of January 1, 2016, Bent Benny Andersen has stepped down as adm. dir. of Pharmanovia A/S.
As of December 31, 2015, Svend Aage Johansen has left the board of directors of Pharmanovia A/S.
As of December 31, 2015, Bent Benny Andersen has left the board of directors of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2014. Gross profit came to DKK -608,728, and the net result was DKK -3,404,393.
Pharmanovia A/S has published its annual report for 2013. Gross profit came to DKK -1,180,354, and the net result was DKK -6,693,739.
As of May 23, 2014, Svend Aage Johansen has joined the board of directors of Pharmanovia A/S.
As of May 23, 2014, Bent Benny Andersen has joined the board of directors of Pharmanovia A/S.
As of May 23, 2014, Bent Benny Andersen is registered as adm. dir. of Pharmanovia A/S.
As of May 23, 2014, Svend Aage Johansen has stepped down as adm. dir. of Pharmanovia A/S.
As of November 1, 2013, Svend Aage Johansen is registered as adm. dir. of Pharmanovia A/S.
As of October 31, 2013, Mads Renlef Henningsen has stepped down as adm. dir. of Pharmanovia A/S.
Pharmanovia A/S has published its annual report for 2012. Gross profit came to DKK -156,507, and the net result was DKK -585,536.
On May 21, 2013, the company changed its name from NORDMEDICA INTERNATIONAL A/S to PHARMANOVIA A/S.
As of January 1, 2013, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Pharmanovia A/S.
As of January 1, 2013, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of Pharmanovia A/S.
As of January 1, 2013, Birgitte Stenbjerre has joined the board of directors of Pharmanovia A/S.
As of January 1, 2013, Mads Renlef Henningsen is registered as adm. dir. of Pharmanovia A/S.
As of January 1, 2013, Bent Benny Andersen has stepped down as director of Pharmanovia A/S.
As of September 14, 2011, Mads Christian Olesen has joined the board of directors of Pharmanovia A/S.
As of September 14, 2011, Bent Benny Andersen is registered as director of Pharmanovia A/S.
As of September 14, 2011, Birgitte Stenbjerre has stepped down as liquidator of Pharmanovia A/S.
On September 14, 2011, the company changed its name from NMAS A/S to NORDMEDICA INTERNATIONAL A/S.
On September 14, 2011, Pharmanovia A/S exited liquidation.
As of May 28, 2010, Svend Aage Johansen has left the board of directors of Pharmanovia A/S.
As of May 28, 2010, Bent Benny Andersen has left the board of directors of Pharmanovia A/S.
As of May 28, 2010, Birgitte Stenbjerre has left the board of directors of Pharmanovia A/S.
As of May 28, 2010, Birgitte Stenbjerre is registered as liquidator of Pharmanovia A/S.
As of May 28, 2010, Bent Benny Andersen has stepped down as director of Pharmanovia A/S.
On May 28, 2010, Pharmanovia A/S entered liquidation.
As of July 6, 2009, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Pharmanovia A/S.
As of July 6, 2009, Svend Aage Johansen has joined the board of directors of Pharmanovia A/S.
As of July 6, 2009, Bent Benny Andersen has joined the board of directors of Pharmanovia A/S.
As of July 6, 2009, Birgitte Stenbjerre has joined the board of directors of Pharmanovia A/S.
As of July 6, 2009, Bent Benny Andersen is registered as director of Pharmanovia A/S.
Pharmanovia A/S was founded on July 6, 2009.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Companies in the same industry and area
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
CVR 37285145
